Biotech Values

[rwwine]

Pending GENR Deal

As each day passes I become more concerned that GENR's management team is hurting the companies chances for getting Squalamine to market soon than later. The "deal" needed to get the Squalamine product into a Phase III study for the AMD indication appears to be on hold for some reason or another. Is a Phase II trial in the great USA really necessary?

The additional 5 million shares sold at $4.04 also has me a bit concerned. I believe that if a deal was around the corner, this recent round of financing was not necessary (IMHO).

Are any of you feeling this way or am I just too impatient?

My interest is truly long term (> 2 years).

Rich